Lillie James Woodruff, MapLight Therapeutics, Inc.'s Chief Scientific Officer, executed sales totaling 4,413 shares of the company's Voting Common Stock across April 15 and 16, 2026, generating $122,573 in gross proceeds, according to a Form 4 filing with the Securities and Exchange Commission.
The transactions were carried out in multiple tranches at prices spanning $26.82 to $27.49 per share. On April 15, Woodruff sold 1,730 shares at a weighted average price of $26.82; transaction prices on that day ranged from $26.33 to $27.29. The following day, April 16, she sold two lots: 686 shares at a weighted average price of $27.01, with execution prices between $26.2201 and $27.2197, and 2,097 shares at a weighted average price of $27.49, with prices recorded between $27.22 and $27.9898.
Footnotes attached to the SEC filing indicate these dispositions represented the number of shares required to be sold to satisfy statutory tax withholding obligations arising from the vesting of restricted stock units. The filing also notes that 808 shares were acquired under the issuer's stock purchase plan on March 31, 2026.
Following the reported sales, Woodruff is listed as directly owning 295,157 shares of MapLight Therapeutics. Since the April transactions, MPLT shares have advanced to $30.05, trading near a 52-week high of $31.13 and showing a year-to-date return of 71%.
Third-party analysis cited in the filing environment indicates a divergence in valuation perspectives. InvestingPro analysis characterizes the stock as appearing overvalued relative to its Fair Value estimate and ranks it among the most overvalued names tracked by the platform. The platform also references 12 additional InvestingPro Tips available for subscribers seeking deeper evaluation of MPLT's investment profile.
Analyst attention to MapLight has accompanied recent market moves. TD Cowen initiated coverage with a Buy rating, drawing attention to the company’s therapeutic pipeline focused on central nervous system and neuropsychiatric indications and highlighting the lead asset, ML-007C-MA, which is intended to enhance schizophrenia treatment. TD Cowen's initiation emphasizes the potential of that asset as a driver of future value, and the firm notes an anticipated Phase II data readout in the third quarter of this year.
Separately, Stifel reaffirmed its Buy rating and kept a $28.00 price target following MapLight’s fourth-quarter update. Stifel reiterated that Phase II data for ML-007C-MA remains on schedule for a topline readout in the third quarter of 2026 and is monitoring the candidate for potential differentiation in tolerability, safety, or once-daily dosing.
These analyst actions and the timing of clinical data contribute to continued market interest in MapLight Therapeutics, even as the Form 4 filing documents an insider sale tied to routine tax-withholding requirements rather than an open-market divestiture for other stated reasons.
Contextual note - The disclosures in the SEC filing and the analyst commentary together paint a picture of a company receiving both positive attention from coverage initiations and reassessments of valuation. The filing itself attributes the sales to tax-withholding needs linked to equity compensation vesting, and the company’s lead program is positioned to provide a near-term catalyst with the scheduled Phase II topline readout.